Advertisement
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Holmberg BJ, Maggs DJ. The use of corticosteroids to treat ocular inflammation. Vet Clin North Am Small Anim Pract. 2004;34(3):693–705. doi:10.1016/j.cvsm.2003.12.007
-
2.
Sulaiman RS, Kadmiel M, Cidlowski JA. Glucocorticoid receptor signaling in the eye. Steroids. 2018;133:60–66. doi:10.1016/j.steroids.2017.11.002
-
3.
McGhee CNJ. Pharmacokinetics of ophthalmic corticosteroids. Br J Ophthalmol. 1992;76(11):681–684. doi:10.1136/bjo.76.11.681
-
4.
Sebbag L, Allbaugh RA, Wehrman RF, et al. Fluorophotometric assessment of tear volume and turnover rate in healthy dogs and cats. J Ocul Pharmacol Ther. 2019;35(9):497–502. doi:10.1089/jop.2019.0038
-
5.
Krishna N. Rate of lacrimal excretion of ophthalmic vehicles. Am J Ophthalmol. 1968;65(6):942–944. doi:10.1016/0002-9394(68)92234-4
-
6.
Ahmed I, Patton TF. Importance of the noncorneal absorption route in topical ophthalmic drug delivery. Invest Ophthalmol Vis Sci. 1985;26(4):584–587.
-
7.
Schoenwald RD, Deshpande GS, Rethwisch DG, Barfknecht CF. Penetration into the anterior chamber via the conjunctival/scleral pathway. J Ocul Pharmacol Ther. 1997;13(1):41–59. doi:10.1089/jop.1997.13.41
-
8.
Burstein NL, Anderson JA. Corneal penetration and ocular bioavailability of drugs. J Ocul Pharmacol. 1985;1(3):309–326. doi:10.1089/jop.1985.1.309
-
9.
Farkouh A, Frigo P, Czejka M. Systemic side effects of eye drops: a pharmacokinetic perspective. Clin Ophthalmol. 2016;10:2433–2441. doi:10.2147/OPTH.S118409
-
10.
Ramsay E, del Amo EM, Toropainen E, et al. Corneal and conjunctival drug permeability: systematic comparison and pharmacokinetic impact in the eye. Eur J Pharm Sci. 2018;119:83–89. doi:10.1016/j.ejps.2018.03.034
-
11.
Anderson JA. Systemic absorption of topical ocularly applied epinephrine and dipivefrin. Arch Ophthalmol. 1980;98(2):350–353. doi:10.1001/archopht.1980.01020030346024
-
12.
Ohman L, Edqvist L-E, Johnansson EB. Absorption of topically applied hydrocortisone from the eye of the rhesus monkey. Acta Ophthalmol (Copenh). 1982;60(1):106–112. doi:10.1111/j.1755-3768.1982.tb05786.x
-
13.
Lanuza R, Rankin AJ, KuKanich B, Meekins JM. Evaluation of systemic absorption and renal effects of topical ophthalmic flurbiprofen and diclofenac in healthy cats. Vet Ophthalmol. 2016;19:24–29. doi:10.1111/vop.12295
-
14.
Hsu KK, Pinard CL, Johnson RJ, Allen DG, Kukanich BK, Nykamp SG. Systemic absorption and adverse ocular and systemic effects after topical ophthalmic administration of 0.1% diclofenac to healthy cats. Am J Vet Res. 2015;76(3):253–265. doi:10.2460/ajvr.76.3.253
-
15.
Griggs AN, Yaw TJ, Haynes JS, Ben-Shlomo G, Tofflemire KL, Allbaugh RA. Bioavailability and biochemical effects of diclofenac sodium 0.1% ophthalmic solution in the domestic chicken (Gallus gallus domesticus). Vet Ophthalmol. 2017;20(2):171–176. doi:10.1111/vop.12387
-
16.
Vaajanen A, Vapaatalo H. A single drop in the eye—effects on the whole body? Open Ophthalmol J. 2017;11(1):305–314. doi:10.2174/1874364101711010305
-
17.
Urtti A, Salminen L. Minimizing systemic absorption of topically administered ophthalmic drugs. Surv Ophthalmol. 1993;37(6):435–456. doi:10.1016/0039-6257(93)90141-s
-
18.
Sebbag L, Kirner NS, Allbaugh RA, Reis A, Mochel JP. Kinetics of fluorescein in tear film after eye drop instillation in Beagle dogs: does size really matter? Front Vet Sci. 2019;6:457. doi:10.3389/fvets.2019.00457
-
19.
Sebbag L, Kirner NS, Wulf LW, Mochel JP. Tear film pharmacokinetics and systemic absorption following topical administration of 1% prednisolone acetate ophthalmic suspension in dogs. Front Vet Sci. 2020;7:571350. doi:10.3389/fvets.2020.571350
-
20.
Spiess BM, Nyikos S, Stummer E, Sahin A, Naegeli H. Systemic dexamethasone concentration in horses after continued topical treatment with an ophthalmic preparation of dexamethasone. Am J Vet Res. 1999;60(5):571–576.
-
21.
Janes RG, Stiles JF. The penetration of cortisol into normal and pathologic rabbit eyes. Am J Ophthalmol. 1963;56(1):84–90. doi:10.1016/0002–9394(63)91306–0
-
22.
Sigurdsson HH, Konrádsdóttir F, Loftsson T, Stefánsson E. Topical and systemic absorption in delivery of dexamethasone to the anterior and posterior segments of the eye. Acta Ophthalmol Scand. 2007;85(6):598–602. doi:10.1111/j.1600-0420.2007.00885.x
-
23.
Weijtens O, Schoemaker RC, Romijn FPHTM, Cohen AF, Lentjes EGWM, van Meurs JC. Intraocular penetration and systemic absorption after topical application of dexamethasone disodium phosphate. Ophthalmology. 2002;109(10):1887–1891. doi:10.1016/s0161-6420(02)01176-4
-
24.
Steelman J, Kappy M. Adrenal suppression and growth retardation from ocular corticosteroids. J Pediatr Ophthalmol Strabismus. 2001;38(3):177–178.
-
25.
Baba S, Mishima H, Okimoto M, Miyachi Y. Plasma steroid levels and clinical effects after topical application of betamethasone. Graefes Arch Clin Exp Ophthalmol. 1983;220(5):209–214. doi:10.1007/BF02308076
-
26.
Bahar I, Rosenblat I, Erenberg M, et al. Effect of dexamethasone eyedrops on blood glucose profile. Curr Eye Res. 2007;32(9):739–742. doi:10.1080/02713680701573704
-
27.
Murphy CJ, Feldman EC, Bellhorn R. Iatrogenic Cushing’s syndrome in a dog caused by topical ophthalmic medications. J Am Anim Hosp Assoc. 1990;26:640–642.
-
28.
Sohlberg E, Halldin MM, Annas A, et al. The impact of the site of blood sampling on pharmacokinetic parameters following sublingual dosing to dogs. J Pharmacol Toxicol Methods. 2013;67(1):1–4. doi:10.1016/j.vascn.2012.10.004
-
29.
Hedges AR, Pypendop BH, Shilo Y, Stanley SD, Ilkiw JE. Impact of the blood sampling site on time-concentration drug profiles following intravenous or buccal drug administration. J Vet Pharmacol Ther. 2014;37(2):145–150. doi:10.1111/jvp.12075
-
30.
Messenger KM, Davis JL, Lafevers DH, Barlow BM, Posner LP. Intravenous and sublingual buprenorphine in horses: pharmacokinetics and influence of sampling site. Vet Anaesth Analg. 2011;38(4):374–384. doi:10.1111/j.1467-2995.2011.00613.x
-
31.
Hermanson JW, de Lahunta A, Evans HE. The veins. In: Hermanson JW, de Lahunta A, Evans HE, eds. Miller and Evans’ Anatomy of the Dog. 5th ed. Elsevier; 2020:1170–1227.
-
32.
Van der Heyden S, Croubels S, Gadeyne C, et al. Influence of P-glycoprotein modulation on plasma concentrations and pharmacokinetics of orally administered prednisolone in dogs. Am J Vet Res. 2012;73(6):900–907. doi:10.2460/ajvr.73.6.900
-
33.
Stringer W, Bryant R. Dose uniformity of topical corticosteroid preparations: difluprednate ophthalmic emulsion 0.05% versus branded and generic prednisolone acetate ophthalmic suspension 1%. Clin Ophthalmol. 2010;4(1):1119–1124. doi:10.2147/OPTH.S12441
-
34.
Marlowe ZT, Davio SR. Dose uniformity of loteprednol etabonate ophthalmic gel (0.5%) compared with branded and generic prednisolone acetate ophthalmic suspension (1%). Clin Ophthalmol. 2014;8:23–29. doi:10.2147/OPTH.S55004
-
35.
Nam A, Kim SM, Jeong JW, Song KH, Koo TS, Seo KW. Comparison of body surface area-based and weight-based dosing format for oral prednisolone administration in small and large-breed dogs. Pol J Vet Sci. 2017;20(3):611–613. doi:10.1515/pjvs-2017-0076
-
36.
Ekstrand C, Pettersson H, Gehring R, Hedeland M, Adolfsson S, Lilliehöök I. Prednisolone in dogs—plasma exposure and white blood cell response. Front Vet Sci. 2021;8:666219. doi:10.3389/fvets.2021.666219
-
37.
Blois S, Mathews KA. Anti-inflammatory therapy. In: Ettinger SJ, Feldman EC, Côté E, eds. Textbook of Veterinary Internal Medicine: Diseases of the Dog and Cat. 8th ed. Elsevier; 2017:1782–1793.
-
38.
Greco DS, Brown SA, Gauze JJ, Weise DW, Buck JM. Dexamethasone pharmacokinetics in clinically normal dogs during low- and high-dose dexamethasone suppression testing. Am J Vet Res. 1993;54(4):580–585.
-
39.
Toutain PL, Alvinerie M, Ruckebusch Y. Pharmacokinetics of dexamethasone and its effect on adrenal gland function in the dog. Am J Vet Res. 1983;44(2):212–217.
-
40.
Quantz KR, Anderson A, Harman CD, et al. Localized alopecia and suppression of hypothalamic pituitary adrenal axis in canines following treatment with difluprednate 0.05% ophthalmic emulsion (Durezol®). In: Proceedings of the ACVO 51st Annual Conference & Trade Show. American College of Veterinary Ophthalmologists; 2020:60.
-
41.
Eichenbaum JD, Macy DW, Severin GA, Paulsen ME. Effect in large dogs of ophthalmic prednisolone acetate on adrenal gland and hepatic function. J Am Anim Hosp Assoc. 1988;24(6):705–709.
-
42.
Roberts SM, Lavach JD, Macy DW, Severin GA. Effect of ophthalmic prednisolone acetate on the canine adrenal gland and hepatic function. Am J Vet Res. 1984;45(9):1711–1714.
-
43.
Glaze MB, Crawford MA, Nachreiner RF, Casey HW, Nafe LA, Kearney MT. Ophthalmic corticosteroid therapy: systemic effects in the dog. J Am Vet Med Assoc. 1988;192(1):73–75.
-
44.
Fukuhara D, Takiura T, Keino H, Okada AA, Yan K. Iatrogenic Cushing’s syndrome due to topical ocular glucocorticoid treatment. Pediatrics. 2017;139(2):e20161233.doi:10.1542/peds.2016-1233
-
45.
Ozerdem U, Levi L, Cheng L, et al. Systemic toxicity of topical and periocular corticosteroid therapy in an 11-year-old male with posterior uveitis. Am J Ophthalmol. 2000;130(2):240–241. doi:10.1016/s0002-9394(00)00501-8
-
46.
Rankin AJ, Kukanich KS, Schermerhorn T, et al. Evaluation of diabetes mellitus regulation in dogs treated with ophthalmic preparations of prednisolone acetate versus diclofenac sodium. Am J Vet Res. 2019;80(12):1129–1135. doi:10.2460/ajvr.80.12.1129
-
47.
Kymionis GD, Panagiotoglou T, Tsilimbaris MK. The effect of intense, short-term topical dexamethasone disodium phosphate eyedrops on blood glucose level in diabetic patients. Ophthalmologica. 2007;221(6):426–429. doi:10.1159/000107505
-
48.
Krupin T, Mandell AI, Podos SM, Becker B. Topical corticosteroid therapy and pituitary-adrenal function. Arch Ophthalmol. 1976;94(6):919–920. doi:10.1001/archopht.1976.03910030459003
-
49.
Gold AJ, Langlois DK, Refsal KR. Evaluation of basal serum or plasma cortisol concentrations for the diagnosis of hypoadrenocorticism in dogs. J Vet Intern Med. 2016;30(6):1798–1805. doi:10.1111/jvim.14589
-
50.
Sebbag L, Soler EA, Allbaugh RA, Mochel JP. Impact of acute conjunctivitis on ocular surface homeostasis in dogs. Vet Ophthalmol. 2020;23(5):828–833. doi:10.1111/vop.12804
-
51.
Sebbag L, Moody LM, Mochel JP. Albumin levels in tear film modulate the bioavailability of medically-relevant topical drugs. Front Pharmacol. 2020;10:1560. doi:10.3389/fphar.2019.01560
-
52.
Sebbag L, Allbaugh RA, Weaver A, Seo YJ, Mochel JP. Histamine-Induced Conjunctivitis and breakdown of blood–tear barrier in dogs: a model for ocular pharmacology and therapeutics. Front Pharmacol. 2019;10:752. doi:10.3389/fphar.2019.00752
-
53.
Page L, Allbaugh RA, Mochel JP, Peraza J, Bertram M, Sebbag L. Impact of diurnal variation, sex, tear collection method, and disease state on tear protein levels in dogs. Vet Ophthalmol. 2020;23(6):994–1000. doi:10.1111/vop.12840
-
54.
Schlaghecke R, Kornely E, Santen RT, Ridderskamp P. The effect of long-term glucocorticoid therapy on pituitary-adrenal responses to exogenous corticotropin-releasing hormone. N Engl J Med. 1992;326(4):226–230.
-
55.
Spencer KB, Thompson FN, Clekis T, Lorenz MD. Adrenal gland function in dogs given methylprednisolone. Am J Vet Res. 1980;41(9):1503–1506.
-
56.
Johnston SD, Mather EC. Canine plasma cortisol (hydrocortisone) measured by radioimmunoassay: clinical absence of diurnal variation and results of ACTH stimulation and dexamethasone suppression tests. Am J Vet Res. 1978;39(11):1766–1770.
-
57.
Richkind M, Edqvist LE. Peripheral plasma levels of corticosteroids in normal Beagles and Greyhounds measured by a rapid competitive protein binding technique. Acta Vet Scand. 1973;14(5):745–757. doi:10.1186/BF03547402
-
58.
Becker MJ, Helland D, Becker D. Serum cortisol (hydrocortisone) values in normal dogs as determined by radioimmunoassay. Am J Vet Res. 1976;37:1101–1102.
-
59.
Chen CL, Kumar M, Willard M, Liao T. Serum hydrocortisone (cortisol) values in normal and adrenopathic dogs as determined by radioimmunoassay. Am J Vet Res. 1978;39(1):179–181.
-
60.
Kemppainen RJ, Sartin JL. Evidence for episodic but not circadian activity in plasma concentrations of adrenocorticotrophin, cortisol and thyroxine in dogs. J Endocrinol. 1984;103(2):219–226. doi:10.1677/joe.0.1030219
Advertisement
Prednisolone and dexamethasone are systemically absorbed after topical application of ophthalmic suspensions in healthy dogs
Abstract
OBJECTIVE
To quantify plasma concentrations of prednisolone and dexamethasone (peripheral and jugular) and cortisol following topical ophthalmic application of 1% prednisolone acetate and 0.1% dexamethasone to healthy adult dogs.
ANIMALS
12 purpose-bred Beagles.
PROCEDURES
Dogs received 1 drop of 1% prednisolone acetate (n = 6) or neomycin polymyxin B dexamethasone (ie, 0.1% dexamethasone; 6) ophthalmic suspension in both eyes every 6 hours for 14 days. Blood samples (peripheral and jugular) were collected on days 0, 1, 7, and 14 and analyzed for plasma prednisolone and dexamethasone concentrations. Plasma cortisol concentrations were measured at the beginning of the study and following topical drug administration.
RESULTS
Both drugs demonstrated systemic absorption. Prednisolone was detected on days 1, 7, and 14 (median plasma concentration, 24.80 ng/mL; range, 6.20 to 74.00 ng/mL), and dexamethasone was detected on days 1, 7, and 14 (2.30 ng/mL; 0 to 17.70 ng/mL). Neither prednisolone nor dexamethasone were detected in plasma samples on day 0 (baseline). Sampling from the jugular vein resulted in higher plasma drug concentrations than from a peripheral vein when samples from each day were combined. Plasma cortisol concentrations were significantly lower than baseline following 14 days of treatment with topical prednisolone acetate and dexamethasone.
CLINICAL RELEVANCE
Prednisolone and dexamethasone are detected in the plasma of healthy dogs following topical ophthalmic administration 4 times/d with prednisolone concentrations being close to a physiologic dose of orally administered prednisolone. Additional research is needed to evaluate the systemic absorption of these medications in dogs with ocular inflammation.
Supplementary Materials
- Supplementary Figure S1 (PDF 197 KB)
- Supplementary Table S1 (PDF 124 KB)
Contributor Notes
Powered by PubFactory